VCI Global shares surge 12.21% premarket after selling Credilab fintech unit in $43.74M management buyout, refocusing on AI platforms.
ByAinvest
Thursday, Feb 5, 2026 4:22 am ET1min read
VCIG--
VCI Global surged 12.21% in premarket trading following the announcement of a $43.74 million management buyout of its fintech subsidiary Credilab. The transaction, valued at 1.1× net tangible assets, includes a 30% equity stake retained by VCI Global, aligning with its strategic shift toward AI-native capital and innovation platforms. The disposal addresses Credilab’s capital-intensive nature, enabling the company to refocus on high-growth sectors like AI infrastructure, robotics, and clean energy. Management emphasized the move strengthens balance sheet discipline and reallocates capital to scalable, asset-light businesses, directly supporting the stock’s sharp premarket rise.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet